WO2016195194A3 - Nouveaux antagonistes de tlr2 - Google Patents
Nouveaux antagonistes de tlr2 Download PDFInfo
- Publication number
- WO2016195194A3 WO2016195194A3 PCT/KR2015/014202 KR2015014202W WO2016195194A3 WO 2016195194 A3 WO2016195194 A3 WO 2016195194A3 KR 2015014202 W KR2015014202 W KR 2015014202W WO 2016195194 A3 WO2016195194 A3 WO 2016195194A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antagonists
- novel
- present
- tlr2 antagonists
- tlr2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des antagonistes de TLR2, qui sont de nouvelles petites molécules et, en particulier : 19 nouveaux antagonistes de TLR2 ; une composition pharmaceutique, contenant les antagonistes, pour prévenir ou traiter des maladies inflammatoires ; et un modulateur de TLR4 contenant les antagonistes. Les nouveaux antagonistes de TLR2 selon la présente invention peuvent être efficacement utilisés en tant que préparation pour administration orale car ils ont un faible poids moléculaire et une biodisponibilité orale élevée, et ils peuvent être utiles dans des compositions pharmaceutiques pour prévenir ou traiter des maladies inflammatoires du fait que la sécrétion d'IL-8 est efficacement inhibée et qu'aucune cytotoxicité in vivo n'est induite. De plus, les nouveaux antagonistes de TLR2 selon la présente invention peuvent être utilisés en tant que modulateur de TLR4.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15894366.2A EP3305767B1 (fr) | 2015-05-29 | 2015-12-23 | Nouveaux antagonistes de tlr2 pour le traitement des maladies inflammatoires |
US15/578,086 US10308655B2 (en) | 2015-05-29 | 2015-12-23 | Method of treating Crohn's disease comprising a TLR2 antagonist |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0076217 | 2015-05-29 | ||
KR20150076217 | 2015-05-29 | ||
KR1020150175045A KR101745524B1 (ko) | 2015-05-29 | 2015-12-09 | 신규한 tlr2 길항제 |
KR10-2015-0175045 | 2015-12-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016195194A2 WO2016195194A2 (fr) | 2016-12-08 |
WO2016195194A3 true WO2016195194A3 (fr) | 2017-01-26 |
Family
ID=57440661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/014202 WO2016195194A2 (fr) | 2015-05-29 | 2015-12-23 | Nouveaux antagonistes de tlr2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016195194A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070167409A1 (en) * | 2003-10-24 | 2007-07-19 | Eisai Co., Ltd. | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions |
WO2009019260A2 (fr) * | 2007-08-03 | 2009-02-12 | Opsona Therapeutics Limited | Composition et procédé pour le traitement d'une lésion de reperfusion et d'un dommage tissulaire |
KR20110071108A (ko) * | 2008-10-06 | 2011-06-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도 |
KR20110081336A (ko) * | 2008-11-04 | 2011-07-13 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 toll―유사 수용체 2 발현의 조절 |
-
2015
- 2015-12-23 WO PCT/KR2015/014202 patent/WO2016195194A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070167409A1 (en) * | 2003-10-24 | 2007-07-19 | Eisai Co., Ltd. | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions |
WO2009019260A2 (fr) * | 2007-08-03 | 2009-02-12 | Opsona Therapeutics Limited | Composition et procédé pour le traitement d'une lésion de reperfusion et d'un dommage tissulaire |
KR20110071108A (ko) * | 2008-10-06 | 2011-06-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도 |
KR20110081336A (ko) * | 2008-11-04 | 2011-07-13 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 toll―유사 수용체 2 발현의 조절 |
Non-Patent Citations (1)
Title |
---|
DATABASE Chemical Abstract XP055467834, retrieved from STN Database accession no. 1147401-24-8 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016195194A2 (fr) | 2016-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
WO2017100726A8 (fr) | Méthodes de traitement de la maladie de huntington | |
TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
WO2017053868A8 (fr) | Dérivés d'acide oléanolique modifié en c4 pour l'inhibition de l'il-17 et d'autres utilisations | |
WO2017132432A8 (fr) | Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma | |
MD4754C1 (ro) | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică | |
WO2018111315A8 (fr) | DÉRIVÉS ÉNONE DE PYRIMIDINE TRICYCLIQUE POUR L'INHIBITION DE RORγ ET D'AUTRES UTILISATIONS | |
WO2011025286A3 (fr) | Glycolipides dérivés de l'acide lipotéichoïque et compositions contenant ces glycolipides | |
MX2013003635A (es) | Compuestos de n-heteroarilo. | |
IN2014KN01075A (fr) | ||
WO2015033302A3 (fr) | Compositions de fulvestrant | |
CA2920410C (fr) | Derive thienopiperidine et son utilisation | |
EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
WO2016112875A3 (fr) | Dérivé diphényle et utilisations associées | |
UA117154C2 (uk) | Антагоністи s1p3 | |
SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
EP4272832A3 (fr) | Composés antimicrobiens, compositions et leurs utilisations | |
WO2016195194A3 (fr) | Nouveaux antagonistes de tlr2 | |
WO2016005962A3 (fr) | Formulations liquides stables de cyclophosphamide et procédés associés | |
WO2020127819A3 (fr) | Composition pharmaceutique comprenant de l'apixaban | |
MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
MX2015009348A (es) | Composiciones hemostaticas. | |
WO2015152577A3 (fr) | Composition destinée à prévenir et à traiter des maladies osseuses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15894366 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15578086 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015894366 Country of ref document: EP |